Remember meForgot password?
    Log in with Twitter
| Press Release

AmeriCann CEO Tim Keogh to Present at Rocky Mountain MicroCap Conference II to Be Held in Denver, Colorado on April 24, 2018

Growing Political Support for Legalization Boosting Interest in Cannabis Industry Investments

DENVER, CO / ACCESSWIRE / April 23, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse style cannabis cultivation and processing properties, today announced that it will be presenting at the Rocky Mountain MicroCap Conference II in Denver, Colorado on Tuesday, April 24th, 2018. For more information please visit:

The Conference is an invitation-only investment forum designed for public microcap companies to present to a large gathering of investors, many of whom have a heightened degree of interest in cannabis industry investments based on the growing sense of the inevitability of legalization.

Tim Keogh, CEO of AmeriCann, will be one of the featured speakers at the conference and will discuss the increasing momentum in Washington, DC toward the end of cannabis prohibition, states' rights and other important industry trends.

He will also provide an update on the company's highly anticipated Massachusetts Medical Cannabis Center (MMCC) large-scale campus style cannabis business park and research center the company is developing 47 miles from Boston.

The event organizers are expecting to host approximately 75 investors--mainly buy side portfolio and fund managers, analysts, family offices, brokers, and high net worth individual investors looking for growth opportunities in the microcap space. Investors with interest in attending should call Stephen Hart of Hayden IR at 917-658-7878.

AmeriCann, with offices in Denver and Boston, has emerged as a national leader in cannabis innovation. They view the MMCC project as a showcase for the future of cannabis cultivation and processing.

Massachusetts is transitioning from medical to full adult use cannabis on July 1, 2018, and industry experts believe it will become the epicenter for cannabis innovation and research for the entire northeast US with annual sales of over $1 billion by 2020.

The MMCC project is approved for 1 million square feet, which will be developed in phases and is expected to be one of the largest, most energy efficient and technologically advanced cannabis cultivation, processing, and research facilities in the nation. The company plans to replicate their technology and systems with expansion to other states.

About AmeriCann

AmeriCann (OTCQX: ACAN) is a publicly traded Agricultural Technology (Ag-Tech) company that is developing a new generation of sustainable, state-of-the-art medical cannabis cultivation and processing properties.

AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company's commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at:, or follow AmeriCann on Twitter@ACANinfo.

About Massachusetts Medical Cannabis Center (MMCC)

The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. Voters in Massachusetts approved legalizing the adult use of recreational marijuana in November of 2016. The state is on track to open the first cannabis storefronts for Adult-Use by July 1, 2018, making Massachusetts the first state in the Northeast to legalize cannabis.

AmeriCann's Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures. The company is planning to replicate the Canopy platform in additional states.

The first phase of the project consists of 30,000 sq. ft. of cultivation, processing and research infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on demand.

About Solanna

AmeriCann has developed and owns ''Solanna'', a new comprehensive line of nutraceutical-grade cannabis infused products. AmeriCann has created the brand, packaging concepts and invested significantly in Standard Operating Procedures and Good Manufacturing Practices to ensure safety, consistency and efficacy across the product offering.

The intellectual property for Solanna will be licensed by AmeriCann to regulated cannabis businesses and will initially focus on providing healthier alternatives to smoking that include:

  • Capsules
  • Topical lotions and balms
  • Sublingual tinctures
  • Oral dissolving film
  • Trans-dermal applications

The Company plans to expand the product line to include edible products, health drinks, and branded concentrates. The products are designed to allow consumers to manage dosage through micro-dosing and to improve efficacy by incorporating blends of other plants, essential oils and other supplements that enhance and compliment the benefits of cannabis.

The Solanna line of products will be offered exclusively through AmeriCann's Preferred Partners.

Forward-Looking Statements

This press release contains ''forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the ''Exchange Act'') (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words ''believe,'' ''anticipate,'' ''estimate,'' ''expect,'' ''intend,'' ''plan,'' ''project,'' ''prospects,'' ''outlook,'' and similar words or expressions, or future or conditional verbs such as ''will,'' ''should,'' ''would,'' ''may,'' and ''could'' are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's recently filed Registration Statement on Form S-1, which the Company has filed with the SEC and which may be viewed at

Contact Information:

AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
@ACANinfo on Twitter

Hayden IR
(917) 658-7878

SOURCE: AmeriCann, Inc.

Latest News
Top News